Astellas, Pfizer's Xtandi Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer

 

• Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
• After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT
• XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer
• Data continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, notably those with high-volume disease, no prior docetaxel use, and synchronous disease
• Long-term data reinforce XTANDI (enzalutamide) plus ADT as a standard of care

https://www.prnewswire.com/news-releases/astellas-and-pfizers-xtandi-enzalutamide-shows-long-term-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer-302463546.html